Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral therapy
protease inhibitor |
| gptkbp:approvalYear |
2007
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AX08
|
| gptkbp:bioavailability |
60-80%
|
| gptkbp:brand |
gptkb:Isentress
|
| gptkbp:CASNumber |
518048-05-0
|
| gptkbp:developer |
gptkb:Merck_&_Co.
|
| gptkbp:drugClass |
integrase strand transfer inhibitor
|
| gptkbp:eliminationHalfLife |
9 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C20H20FKN6O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
Raltegravir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV integrase
|
| gptkbp:metabolism |
liver (UGT1A1-mediated)
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinBinding |
83%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache insomnia increased liver enzymes |
| gptkbp:synonym |
gptkb:MK-0518
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:J05AE12
gptkb:J05AP08 |
| gptkbp:bfsLayer |
6
|